Related Experiment Video

Updated: May 14, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Could platelet indices be new biomarkers for inflammatory bowel diseases?

Z A Öztürk1, M S Dag, M E Kuyumcu

  • 1Department of Internal Medicine, Division of Geriatric Medicine, Faculty of Medicine, Gaziantep University, Sahinbey, Gaziantep, Turkey. zaodr79@yahoo.com

European Review for Medical and Pharmacological Sciences
|February 22, 2013
PubMed

Insights

Platelet indices like MPV, PDW, and PCT show significant changes in inflammatory bowel diseases (IBD), aiding in monitoring disease activity and severity. These can serve as accessible biomarkers for tracking IBD progression.

Area of Science:

  • Gastroenterology
  • Hematology
  • Immunology

Background:

  • Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic conditions requiring effective monitoring.
  • Current biomarkers for IBD diagnosis and activity assessment are varied, with a need for accessible, non-invasive markers.
  • Platelets are recognized for their role in inflammatory processes.

Purpose of the Study:

  • To investigate the utility of platelet indices—mean platelet volume (MPV), platelet distribution width (PDW), and platelet-crit (PCT)—as biomarkers for IBD.
  • To determine if these platelet indices can effectively monitor disease activity and severity in UC and CD patients.

Main Methods:

  • A study involving 175 IBD patients (103 UC, 72 CD) and 40 healthy controls.
  • Assessment of disease activity using endoscopic and clinical evaluations.
  • Measurement of platelet indices (MPV, PDW, PCT) and inflammatory markers in both active and remission phases of IBD.

Main Results:

  • Active UC and CD patients exhibited significantly lower MPV and PDW, and higher PCT compared to controls.
  • During IBD remission, MPV levels were lower, while PDW and PCT levels were higher than in controls.
  • PDW and PCT showed significant correlations with UC disease activity, indicating their potential as monitoring tools.

Conclusions:

  • Platelet indices demonstrate noteworthy changes in patients with IBD.
  • These indices can be valuable additions to existing inflammatory markers for monitoring IBD.
  • Platelet indices are particularly useful for tracking disease progression from active phases to remission.
Abstract

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...